The production of soluble triggering receptor expressed on myeloid cells by lipopolysaccharide-stimulated human neutrophils involves de novo protein synthesis.

Amr Mahdy, Damon Anthony Lowes, Helen Frances Galley, Nigel Robert Webster

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The triggering receptor expressed on myeloid cells (TREM-1) is a recently identified receptor expressed on neutrophils and monocytes. Activation of the receptor induces neutrophils to release the enzyme myeloperoxidase and inflammatory cytokines such as interleukin-8. TREM-1 has an alternatively spliced variant that lacks the transmembrane region, resulting in the receptor being secreted in a soluble form (sTREM-1). Soluble TREM-1 has been detected in plasma during experimental and clinical sepsis and has been advocated as a diagnostic marker of infection for pneumonia and as a prognostic marker for patients with septic shock. We studied TREM-1 surface expression, using flow cytometry, and simultaneously measured sTREM-1 concentrations in culture supernatants of lipopolysaccharide (LPS)-stimulated neutrophils. TREM-1 surface expression was constitutive and was not upregulated upon LPS stimulation. However, sTREM-1 release from neutrophils was significantly upregulated by LPS stimulation (P < 0.0001), an effect that was abrogated by cycloheximide. Soluble TREM-1 is therefore secreted by human neutrophils in response to LPS challenge in a process involving de novo protein synthesis that is not accompanied by an upregulation of the TREM-1 receptor on the surfaces of the cells.

Original languageEnglish
Pages (from-to)492-495
Number of pages3
JournalClinical and Vaccine Immunology
Volume13
DOIs
Publication statusPublished - 2006

Keywords

  • INFLAMMATORY RESPONSES
  • SEPTIC SHOCK
  • CUTTING EDGE
  • SEPSIS
  • TREM-1
  • EPIDEMIOLOGY
  • ACTIVATION
  • PATTERNS
  • SURFACE

Cite this